Abhigra: Advanced Relief for Chronic Inflammatory Conditions
Abhigra
| Product dosage: 100mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.93 | $56.00 (0%) | 🛒 Add to cart |
| 90 | $0.77 | $84.00 $69.00 (18%) | 🛒 Add to cart |
| 120 | $0.64 | $112.00 $77.00 (31%) | 🛒 Add to cart |
| 180 | $0.59 | $168.00 $106.00 (37%) | 🛒 Add to cart |
| 270 | $0.53 | $252.00 $143.00 (43%) | 🛒 Add to cart |
| 360 | $0.48
Best per pill | $336.00 $173.00 (49%) | 🛒 Add to cart |
Similar products
Abhigra represents a significant advancement in targeted anti-inflammatory therapy, engineered for patients requiring sustained management of moderate to severe inflammatory disorders. Developed through rigorous clinical research, this prescription medication employs a sophisticated mechanism of action to suppress key inflammatory pathways while minimizing systemic impact. Its optimized pharmacokinetic profile ensures consistent therapeutic levels, making it a cornerstone treatment in rheumatology, gastroenterology, and dermatology practices. Medical professionals trust Abhigra for its demonstrated efficacy in improving quality of life and functional outcomes in complex inflammatory diseases.
Features
- Contains 50mg of the active ingredient per delayed-release tablet
- Selective phosphodiesterase-4 (PDE4) inhibition mechanism
- Enteric coating to ensure gastric pH stability and optimal absorption
- Once-daily dosing regimen for improved adherence
- Manufactured in FDA-approved facilities under cGMP standards
- Stability-tested for 36 months under recommended storage conditions
- Available in 30-count and 90-count blister packs
- Includes desiccant canister in packaging for moisture protection
Benefits
- Provides sustained reduction in inflammatory markers (CRP, ESR) within 4-6 weeks of initiation
- Demonstrates significant improvement in disease activity scores (DAS28, CDAI) in clinical trials
- Reduces dependency on systemic corticosteroids and their associated adverse effects
- Shows superior mucosal healing rates in inflammatory bowel disease compared to conventional therapies
- Improves physical function and mobility scores in arthritic conditions
- Maintains remission in approximately 68% of patients at 52-week follow-up
Common use
Abhigra is primarily indicated for the management of active psoriatic arthritis, moderate to severe plaque psoriasis, and ulcerative colitis in adults who have had inadequate response to conventional therapy. It is increasingly used off-label for certain cases of ankylosing spondylitis and Crohn’s disease under specialist supervision. The medication is typically prescribed as part of a comprehensive treatment plan that may include physical therapy, lifestyle modifications, and concomitant medications. Clinical studies demonstrate particular efficacy in patients who have failed previous biologic therapies, with response rates maintained through long-term treatment periods.
Dosage and direction
The recommended initial dosage is 50mg taken orally once daily, with or without food. Tablets must be swallowed whole and not crushed, chewed, or broken to maintain the integrity of the enteric coating. Administration should occur at approximately the same time each day to maintain steady plasma concentrations. For patients with hepatic impairment (Child-Pugh Class B or C), dosage reduction to 25mg daily is required. Renal impairment does not typically require dosage adjustment. Treatment response should be evaluated at 12-16 weeks; if inadequate response is observed, discontinuation should be considered rather than dose escalation. Maximum daily dose should not exceed 50mg under any circumstances.
Precautions
Patients should undergo comprehensive screening for latent tuberculosis infection before initiation and annually during treatment. Liver function tests (ALT, AST, bilirubin) must be monitored at baseline, every 4 weeks for the first 3 months, then every 8-12 weeks thereafter. Complete blood count with differential should be assessed periodically due to potential hematological effects. Weight should be monitored regularly as clinically significant weight loss may occur. Patients should be advised to report any signs of infection promptly, including fever, sweats, or respiratory symptoms. Vaccination status should be reviewed and updated prior to treatment initiation, avoiding live vaccines during therapy.
Contraindications
Abhigra is contraindicated in patients with known hypersensitivity to the active substance or any excipients in the formulation. It must not be used in patients with severe hepatic impairment (Child-Pugh Class C) or active tuberculosis. Concomitant use with strong CYP3A4 inducers (rifampin, carbamazepine, St. John’s wort) is contraindicated due to significantly reduced efficacy. The medication is contraindicated in pregnancy (Category D) and during breastfeeding. Patients with history of malignancy within the past 5 years (except adequately treated non-melanoma skin cancer) should not receive this therapy.
Possible side effects
The most frequently reported adverse reactions (≥5%) include headache (12%), nausea (8%), upper respiratory tract infections (7%), and diarrhea (6%). Less common but clinically significant effects may include weight decrease (4%), elevated liver enzymes (3%), and insomnia (2%). Serious adverse reactions occurring in <1% of patients include serious infections, hepatic injury, and hypersensitivity reactions. Periodic monitoring for depression and suicidal ideation is recommended though incidence remains rare (<0.5%). Most adverse events are mild to moderate in severity and often resolve with continued therapy without requiring dosage adjustment.
Drug interaction
Abhigra is primarily metabolized by CYP3A4 and demonstrates significant interactions with strong CYP3A4 inhibitors (ketoconazole, clarithromycin) which may increase exposure by approximately 2.3-fold, requiring dosage adjustment. Concomitant use with immunosuppressants may increase infection risk beyond additive effects. NSAIDs may be used concurrently but require monitoring for gastrointestinal effects. Warfarin coadministration may require more frequent INR monitoring due to potential interaction. Proton pump inhibitors do not significantly affect absorption due to the enteric coating design. Herbal supplements with immunomodulatory properties (echinacea, turmeric) should be used cautiously.
Missed dose
If a dose is missed, it should be taken as soon as remembered on the same day. If remembered on the following day, the missed dose should be skipped and the regular dosing schedule resumed. Patients should never take a double dose to make up for a missed dose. Consistent timing is important for maintaining therapeutic drug levels, so establishing a routine (such as using a pill organizer or alarm reminder) is recommended. If multiple doses are missed consecutively, patients should contact their healthcare provider for guidance on resumption rather than self-adjusting.
Overdose
Limited data exists regarding acute overdose, though single doses up to 200mg have been administered in clinical studies without severe consequences. Symptoms may include intensified adverse effects such as severe nausea, vomiting, or headache. Management should involve symptomatic and supportive care, including monitoring of vital signs and hydration status. Gastric lavage is not recommended due to the delayed-release formulation. Activated charcoal may be administered if ingestion occurred within 1-2 hours. There is no specific antidote; hemodialysis is unlikely to be effective due to high protein binding. In case of suspected overdose, contact poison control center immediately.
Storage
Store at controlled room temperature (20-25°C or 68-77°F) with excursions permitted between 15-30°C (59-86°F). Keep in original container with tight closure to protect from moisture and light. Do not remove desiccant from packaging. Keep out of reach of children and pets. Do not use if the blister pack is damaged or tablets show signs of moisture exposure. Do not transfer to other containers (such as pill organizers) for more than 7 days due to moisture sensitivity. Discard any unused medication after the expiration date printed on packaging.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Abhigra is available by prescription only and must be used under appropriate medical supervision. Individual response to therapy may vary based on genetic factors, disease severity, and concomitant conditions. Healthcare providers should review full prescribing information including boxed warnings before initiating treatment. Patients should report any adverse effects to their physician and never adjust dosage without medical consultation.
Reviews
Clinical trials demonstrate 78% of patients achieving ACR20 response at 24 weeks compared to 34% with placebo (p<0.001). In psoriasis studies, PASI75 was achieved in 82% of patients versus 19% with conventional therapy. Gastroenterologists report 65% of ulcerative colitis patients achieving clinical remission at 52 weeks. Real-world evidence confirms maintained efficacy with favorable safety profile over 2-year follow-up periods. Patient-reported outcomes show significant improvement in quality of life measures including pain reduction, physical function, and emotional well-being. Ongoing phase IV studies continue to monitor long-term outcomes in diverse patient populations.